Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Public ClinicalTrials.gov record NCT02181634. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Patients with advanced or metastatic cholangiocarcinoma (CCA) who are not eligible for curative surgery, transplantation, or ablative therapies will receive nab-paclitaxel and gemcitabine chemotherapy. The purpose of this study is to evaluate the effectiveness and safety of the combination of nab-paclitaxel and gemcitabine. The effectiveness will be determined by improvement in the length of time during and after treatment, that the CCA does not get worse.
Study identification
- NCT ID
- NCT02181634
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 74 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 9, 2014 (Actual)
- Primary completion
- Sep 24, 2016 (Actual)
- Completion
- Oct 1, 2017 (Actual)
- Last update posted
- Oct 3, 2018
2014 – 2017
United States locations
- U.S. sites
- 24
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Colorado Cancer Research Program | Denver | Colorado | 80222 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Advocate Christ Medical Center | Oak Lawn | Illinois | 60453 | — |
| Siouxland Hematology-Oncology Associates | Sioux City | Iowa | 51101 | — |
| Ochsner Medical Center | New Orleans | Louisiana | 70121 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| University Massachusetts Memorial Medical Center | Worcester | Massachusetts | 01655 | — |
| St. Joseph Mercy Health System | Ann Arbor | Michigan | 48106-0995 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| University of Michigan Medical Center | Ann Arbor | Michigan | 48109 | — |
| Metro Minnesota CCOP | Saint Louis Park | Minnesota | 55416 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| Mount Sinai Hospital | New York | New York | 10029 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| University of Pennsylvania, Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| University of Pennsylvania; Abramson Cancer Center at Presbyterian Medical Center | Philadelphia | Pennsylvania | 19104 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | — |
| Vanderbilt University/Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Gundersen Health System | La Crosse | Wisconsin | 54601 | — |
| University of Wisconsin-Madison | Madison | Wisconsin | 53792 | — |
| Aurora Cancer Care | Wauwatosa | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02181634, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 3, 2018 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02181634 live on ClinicalTrials.gov.